Although the daily use of aspirin reduces the risks of myocardial infarction, stroke and vascular death in patients at high risk of developing vascular disease, the use of preventative aspirin therapy in patients with no history of cardiovascular disease is controversial. For this reason, we studied the benefits and risks of aspirin therapy in the primary prevention of cardiovascular disease, in particular for aspirin at low doses.
Introduction
The benefit of aspirin therapy in patients with a history of cardiovascular disease has been well established1,2). An influential meta-analysis of over 100 randomized clinical trials showed that the aspirin therapy reduced the risk of non-fatal myocardial infarction by 34%, and in the setting of secondary prevention reduces non-fatal strokes by 31%, cardiovascular events by 27 % , and cardiovascular deaths by 18%, respectively2). On the other hand, two early randomized trials of aspirin in healthy men, the British Male Doctors' Trial3) and the U.S. Physicians' Health Stud?), had contradictive results regarding whether aspirin could reduce the risk for myocardial infarction. Neither trial had sufficient power to precisely estimate major harms such as gastrointestinal bleeding and hemorrhagic stroke3,4). Recently, three additional large primary prevention trials for aspirin were published5,7). However, a benefit of aspirin therapy for patients without a history of cardiovascular disease has not been still clarified. Further, aspirin doses used in these trials were too high for Japanese.
The aim of this study is to estimate the benefits of lowdose aspirin therapy in primary prevention of cardiovascular disease. Moreover, we especially attempted to evaluate the harms of the low-dose aspirin therapy.
Materials and Methods
We searched the MEDLINE data base from 1966 to 2002 to identify studies on aspirin's ability to prevent cardiovascular events and its likelihood of causing adverse effects. In addition, the reference lists of published primary prevention trials of aspirin therapy3-7) and previous reviews8-11) were researched. Our search was limited to articles published in English-language. The criteria as the trials in the metaanalysis were as follows : (1) [4] [5] [6] [7] . Two large trials that examined the effect of aspirin in patients with diabetes or with stable angina were excluded due to more than 10% of the participants had defined or suspected vascular disease12,13). The British Male Doctors' (BMD) Trial was also excluded because of high dose of aspirin (500 mg per day)3). Results of these randomized clinical trials were combined using a Peto method, and the odds ratio (OR) and 95 % confidence intervals (95 % CI)14) were estimated. Homogeneity was evaluated by a X2 statistic method, in which the weighted difference of each individual estimate from the pooled one was summed up.
Results
Four randomized trials, i.e. PHS, TPT, HOT and PPP, included 47,896 patients, of whom 23,930 were treated with aspirin. The outlines of these trials are summarized in Table   1 . The follow-up periods of these trials were ranging from 3.6 to 6.8 years. Aspirin doses were remarkably different from 75 to 162.5 mg daily. The HOT and PPP studies included women, and all participants in HOT had well controlled hypertension.
Meta-analysis of the 4 trials for the combined outcome of all myocardial infarction produced a summary OR of 0.64 (95 % CI, 0.56 to 0.74) (Fig. 1) . The summary OR and CIs showed significant decrease overall in myocardial infarction.
There was no heterogeneity in odds ratios between trials for myocardial infarction.
The summary ORs (95 % CIs) for the combined outcome of all stroke and all-cause mortality produced by 4 trials were 1.01 (0.86 to 1.19) and 0.94 (0.84 to 1.04), respectively. Significant differences in OR and CIs could not be observed in each outcome. These results were summarized in Fig. 2 and 3 .
Meta-analysis of the 3 trials (except for PPP) for the combined outcome of hemorrhagic stroke or intracranial hemorrhage produced the summary OR of 1.38 (95 % CI, 0.86 to 2.21) (Fig. 4) . We can' t use the PPP trial because of no data on hemorrhagic stroke or intracranial hemorrhage in it.
The summary ORs and CIs of these 3 trials showed no significant increase.
As shown in Fig. 5 , meta-analysis of the 3 trials (except for PHS) for the combined outcome of whole gastrointestinal bleeding produced the summary OR of 2.03 (95 % CI, 1.55 to 2.65). We can' t use the PHS trial because of no data on gastrointestinal bleeding in it. Significant increasing in gastrointestinal bleeding could be detected in the ORs and CIs. There was no heterogeneity in all ORs between trials.
Discussion
In many foreign countries, there are numerous studies on aspirin therapy for the prevention of cardiovascular events.
However due to the high aspirin doses, the findings from these studies could not provide useful information for Japanese. Thus, we tried meta-analysis of aspirin therapy which used the recommended daily doses in Japan, which one less than 324 mg per day. To our best knowledge, this is the first meta-analysis for the harms of low-dose aspirin therapy.
Our results suggest that low-dose aspirin therapy for patients without a history of cardiovascular disease significantly reduces the risk of myocardial infarction, though it has no association with all-cause mortality. However, the results also suggest that it significantly increases the risk of gastrointestinal bleeding. It is difficult to interpret the overall effect of aspirin on stroke due to its subtypes. Data from secondary prevention trials suggest that aspirin not only prevents ischemic strokes but also cause hemorrhagic stroke. The effect of aspirin on the total incidence of stroke depends on the patient's potentiality for risk of each stroke subtype2). Point estimates in PPP and TPT suggested modest decreases in total strokes in spite of the wide CIs5,7). In HOT, no effect of low-dose aspirin on overall rates of stroke was shown6). In PHS, tendency to increase the risk of stroke in low-dose aspirin-treated patients was observed, but did not achieve statistical significance. Hart and colleagues11) combined data obtained the 4 primary prevention trials') and concluded that aspirin has no effect on ischemic strokes in the-middle-aged, relatively low-risk patients (relative risk, 1.03 ; 95% CI, 0.87 to 1.21).
Although the event rates of low-dose aspirin-exposed participants for hemorrhagic strokes including intracranial hemorrhage were higher than those of controls in PHS and TPT, these differences did not show statistical significance in any trial4,5). In HOT and PPP, the risk of hemorrhagic strokes was almost equal between intervention and control groups6,7). Hart and colleagues11) pooled the results of the 4 primary prevention studies and estimated that the relative risk for hemorrhagic stroke due to long-term aspirin use was 1.36 (95% CI, 0.88 to 2.1).
Several systematic reviews have examined the risk of gastrointestinal bleeding with aspirin use15-18 For the primary prevention of vascular disease such as myocardial infarction, we clarified that the low-dose aspirin therapy contributed to significant beneficial effects. These effects were clinically important. The association between all-cause mortality or overall stroke and the low-dose aspirin therapy can not be elucidated because of insufficient numbers of events in the primary prevention trials. Especially more data on hemorrhagic stroke are needed.
In conclusion, our meta-analysis suggests that the low- dose aspirin therapy for primary prevention appears to reduce the risk of myocardial infarction, while it increases the risk of gastrointestinal bleeding. In the case of aspirin therapy, even if low-dose aspirin, we should make our effort to avoid the gastrointestinal bleeding.
